Intellia Therapeutics, Inc. (NTLA) Stock Forecast Oct. 14, 2026
Analysis updated on Oct. 14, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq
Intellia Therapeutics, Inc. (NTLA) stock forecast summary
Our AI ranks Intellia Therapeutics, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Intellia Therapeutics, Inc. is a small-cap company with a market capitalization of $1.67B. It ranks number 5 by market capitalization among the 15 In Vitro & In Vivo Diagnostic Substances issuers in our coverage with a current forecast.
A per-ticker accuracy statistic for NTLA is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +4.5%, buy ≥ +3.4%, sell < +2.1%, strong sell < +0.9% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-13 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, NTLA included.
Follow NTLA freeNTLA price chart and AI forecast
How NTLA ranks among 5379 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Intellia Therapeutics, Inc. (NTLA) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the In Vitro & In Vivo Diagnostic Substances peers listed below that report each metric.
Valuation & Market
| Metric | NTLA | Rank |
|---|---|---|
| Market Cap | $1.67B | 5/15 |
| P/B Ratio | 2.29x | 7/11 |
| EPS | $-2.53 | – |
| Book Value/Share | $5.19 | – |
| Revenue/Share | $0.42 | – |
| FCF/Share | $-2.49 | – |
Profitability & Margins
| Metric | NTLA | Rank |
|---|---|---|
| ROE | -55.0% | 8/11 |
| ROA | -46.7% | 9/13 |
| ROIC | -54.5% | 9/11 |
| Operating Margin | -711.7% | 9/14 |
| Net Margin | -672.2% | 8/11 |
| EBT Margin | -711.7% | 9/14 |
Financial Health
| Metric | NTLA | Rank |
|---|---|---|
| Current Ratio | 6.65x | 3/15 |
| D/E Ratio | 0.18x | 10/12 |
| Financial Leverage | 1.18x | 10/12 |
| Working Capital | $448M | 3/15 |
Cash Flow
| Metric | NTLA | Rank |
|---|---|---|
| Operating Cash Flow | -$347M | 16/16 |
| Free Cash Flow | -$349M | 10/10 |
| Capital Spending | -$2M | 5/10 |
| FCF/Sales | -586.0% | 6/10 |
| CapEx/Sales | 3.4% | 7/10 |
Operational Efficiency
| Metric | NTLA | Rank |
|---|---|---|
| Asset Turnover | 0.07x | 9/12 |
| Receivables Turnover | 8.1x | 4/11 |
| Fixed Assets Turnover | 4.0x | 4/12 |
| Days Sales Outstanding | 45 days | 8/11 |
Income Statement
| Metric | NTLA | Rank |
|---|---|---|
| Total Revenue | $59M | 6/12 |
| Operating Income | -$423M | 14/15 |
| Net Income | -$399M | 12/13 |
| R&D Expense | $347M | 1/16 |
Dividend & Shareholder Information
| Metric | NTLA | Rank |
|---|---|---|
| Shares Outstanding | 140M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $528M | 61.5% of assets |
| Cash & Short-term Investments | $106M | 12.4% of assets |
| Accounts Receivable | $7M | 0.9% of assets |
| Total Liabilities | $129M | 15.1% of assets |
| Short-term Debt | $68M | 7.9% of assets |
NTLA quarterly financials and insider trading
Intellia Therapeutics, Inc. (NTLA) industry peers
Companies classified under the same SEC industry code as Intellia Therapeutics, Inc. (In Vitro & In Vivo Diagnostic Substances): 17 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| NTLA Intellia Therapeutics, Inc. | ▲ | $1.67B |
| IDXX Idexx Laboratories Inc /De | ▼ | $40.99B |
| LNTH Lantheus Holdings, Inc. | ▼ | $6.53B |
| NEOG Neogen Corp | ▲ | $2.56B |
| CLDX Celldex Therapeutics, Inc. | ▲ | $2.22B |
| QDEL Quidelortho Corp | ▲ | $967M |
| ACHV Achieve Life Sciences, Inc. | ▲ | $720M |
| TKNO Alpha Teknova, Inc. | ▲ | $441M |
| MYGN Myriad Genetics Inc | ▲ | $390M |
| IMDX Insight Molecular Diagnostics Inc. | ▲ | $98M |
| ICCC Immucell Corp /De/ | ▲ | $87M |
| AWHL Aspira Women's Health Inc. | ▲ | $12M |
| BMRA Biomerica Inc | ▲ | $8M |
| CDIO Cardio Diagnostics Holdings, Inc. | ▲ | $5M |
| VNRX Volitionrx Ltd | ▶ | $3M |
| QCLS Q/C Technologies, Inc. | ▼ | N/A |
| TRIB Trinity Biotech Plc | ▶ | N/A |
Where NTLA sits on the market map
Intellia Therapeutics, Inc. (NTLA) stock news
Loading...
Intellia Therapeutics, Inc. (NTLA) stock forecast FAQ
What is the Intellia Therapeutics, Inc. (NTLA) stock forecast?
Our AI ranks Intellia Therapeutics, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Intellia Therapeutics, Inc. stock predictions?
A per-ticker accuracy statistic for NTLA is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Intellia Therapeutics, Inc. forecasts updated?
Intellia Therapeutics, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
Which companies are Intellia Therapeutics, Inc.'s industry peers?
17 issuers in our coverage, NTLA included, share the SEC industry code In Vitro & In Vivo Diagnostic Substances. The largest are: Idexx Laboratories Inc /De (IDXX), Lantheus Holdings, Inc. (LNTH), Neogen Corp (NEOG), Celldex Therapeutics, Inc. (CLDX), Quidelortho Corp (QDEL), Achieve Life Sciences, Inc. (ACHV).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.